Replies to post #101 on Neurocrine Biosciences (NBIX)

[surf1944]

4:14PM Neurocrine Biosci announces start of second Phase IIb study of VMAT2 Inhibitor NBI-98854 for treatment Of Tardive Dyskinesia (NBIX) 7.98 +0.11 : Neurocrine Biosciences announced that it has initiated a Phase IIb clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders, and schizophrenia or schizoaffective disorder. Topline data is expected in mid-2013